Clinical Trial

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test whether the combination of the drugs called tacrolimus (Tac), methotrexate (MTX) and new dosing strategy of another drug called (rabbit Anti-thymocyte Globulin \[ATG\]) will help prevent the development and/or improve severity of acute and/or chronic GVHD.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-03-11; most recent amendment 2025-10-06.
Status change: Not Yet Recruiting → Recruiting 2025-10-06
Trial Details
NCT Number NCT06315309
Lead Sponsor University of Alabama at Birmingham
Conditions GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Enrollment 29 participants
Start Date 2025-04-15
Primary Completion 2026-12 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2025-10-08